(16) identified serum ALB level as an independent negative prognostic factor for 12-month overall survival (OS) in patients with B-cell non-Hodgkin lymphoma (NHL) or B-cell acute lymphoblastic leukemia (ALL) receiving CAR-T cell therapy. Here, ALB is linked to acute lymphoblastic leukemia.